Invitation to Conference Call for Updated Clinical Trial Results reported at the International Conference on Malignant Lymphoma

Oslo, Norway, 13 June 2017

Nordic Nanovector ASA (OSE: NANO) will host a conference call on Wednesday, 14 June at 1 pm CET to present updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical trial of Betalutin® in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. These data will be presented at the International Conference on Malignant Lymphoma (ICML) on 14-17 June in Lugano, Switzerland.

Conference call details:

The call is scheduled for Wednesday, 14 June 2017 at 1 pm CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below:

Location Phone Number
Norway +47 2100 2610
Switzerland +41 (0)44 580 7206
Sweden +46 (0)8 5033 6574
United Kingdom +44 (0)330 336 9105
United States and International +1 719-457-1036

Conference ID: 5732602

The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Presentation/2017 from 1 pm CET on 14 June 2017.

For further information, please contact:

IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk

About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.

The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

 


Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe